Category - Developments

Developments

TransMedics receives positive FDA advisory committee vote for OCS Heart System

The FDA’s Circulatory Systems Device Advisory Panel issued a favorable vote in support of approval of TransMedics Group’s (NASDAQ:TMDX) OCS Heart System to the FDA’s Office of Health Technology 2 (Cardiovascular...

April 7, 2021

Developments

IntelGenx ships first CBD filmstrip order to Heritage Cannabis

IntelGenx (TSXV:IGX; OTCQB:IGXT) completed its first shipment, consisting of 75,000 CBD filmstrips, to Heritage Cannabis Holdings (CSE:CANN) for the Canadian and Australian markets. The CBD filmstrips were produced at...

April 1, 2021

Developments

111, Inc., Jianming Pharma to develop chronic disease management platform in China

111, Inc. (NASDAQ:YI), a leading digital healthcare platform company in China, and Jianming Pharmaceutical Group signed a strategic cooperation agreement to develop an online chronic disease management platform for the...

March 25, 2021

Developments

Lineage presents additional interim data with OpRegen in dry AMD with GA

Lineage Cell Therapeutics (NYSE American, TASE:LCTX) presented new positive interim results from its ongoing, 24-patient Phase 1/2a clinical study of its lead product candidate, OpRegen, for the treatment of dry age...

March 23, 2021

Developments

Hepion Pharma reports new positive nonclinical antifibrotic data with CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive results from an in vivo study of CRV431 in a diet-induced animal model of non-alcoholic fatty liver disease (DIAMOND). Hepion’s CRV431 administered orally and once...

March 23, 2021

Developments

Diabeloop, BIOCORP in personalized diabetes management pact

Diabeloop and BIOCORP (FR0012788065 – ALCOR) are collaborating to offer new, simple and personalized treatment options to people living with diabetes. BIOCORP has developed and markets Mallya, an intelligent sensor for...

March 22, 2021

Developments

111 Inc. posts 96.1% jump in Q4 net revenue; beating guidance

Shanghai-based 111 Inc. (NASDAQ:YI) reported net revenue of $405.1-million (U.S.) in the fourth quarter of 2020, which was up 96.1%, from the year earlier quarter, beating its previous guidance of 81% to 90% growth. Net...

March 18, 2021

Developments

Hepion Pharma, ENDRA Life Sciences to collaborate in Hepion’s NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) and ENDRA Life Sciences (NASDAQ:NDRA) signed a collaboration agreement to incorporate ENDRA’s Thermo Acoustic Enhanced UltraSound (TAEUS) as an add-on technology to support...

March 18, 2021

Developments

111, Inc. in strategic partnership with BeiGene

111, Inc. (NASDAQ:YI), a leading digital healthcare platform in China, entered into a strategic cooperation agreement with BeiGene (NASDAQ:BGNE; HKEX:06160), a commercial-stage and development biotechnology company...

March 17, 2021

Developments

111, Inc. achieves full distribution coverage across mainland China

111, Inc. (NASDAQ:YI) opened two new state-of-the-art, technology-driven fulfillment centers in the Northern cities of Xi’an and Shenyang, bringing the company’s total number of fulfillment centers to eight. The...

March 16, 2021

Category - Developments

TransMedics receives positive FDA advisory committee vote for OCS Heart System

IntelGenx ships first CBD filmstrip order to Heritage Cannabis

111, Inc., Jianming Pharma to develop chronic disease management platform in China

Lineage presents additional interim data with OpRegen in dry AMD with GA

Hepion Pharma reports new positive nonclinical antifibrotic data with CRV431

Diabeloop, BIOCORP in personalized diabetes management pact

111 Inc. posts 96.1% jump in Q4 net revenue; beating guidance

Hepion Pharma, ENDRA Life Sciences to collaborate in Hepion’s NASH trial

111, Inc. in strategic partnership with BeiGene

111, Inc. achieves full distribution coverage across mainland China

Follow Us

General

More

Sign up for the BioTuesdays weekly newsletter